Vandenheuvel W J, Skeggs H, Arison B H, Wislocki P G
J Pharm Sci. 1983 Jul;72(7):782-4. doi: 10.1002/jps.2600720716.
Twelve in vitro oxygenated metabolites of 3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1H-imidazol-2-yl)-1,2-benzisoxazole (MK-0436) were produced by incubation of this antiprotozoal agent with the postmitochondrial supernatant (S9) fraction isolated from the livers of rats treated with phenobarbital. Metabolite structure elucidation was achieved using NMR and mass spectrometry. Seven monohydroxy and two dihydroxy metabolites were fully characterized; two other metabolites were partially characterized as dihydroxy derivatives of the drug. The major in vitro metabolite is the 5 axial hydroxy compound, and a minor metabolite is the corresponding ketone. In all cases metabolite formation involved biotransformation on the hexahydrobenzisoxazole ring.
将抗寄生虫药3a,4,5,6,7,7a-六氢-3-(1-甲基-5-硝基-1H-咪唑-2-基)-1,2-苯并异恶唑(MK-0436)与从经苯巴比妥处理的大鼠肝脏中分离得到的线粒体后上清液(S9)组分一起孵育,产生了12种体外氧化代谢产物。代谢产物结构通过核磁共振和质谱进行鉴定。七种单羟基和两种二羟基代谢产物得到了全面表征;另外两种代谢产物被部分表征为该药物的二羟基衍生物。主要的体外代谢产物是5位轴向羟基化合物,次要代谢产物是相应的酮。在所有情况下,代谢产物的形成都涉及六氢苯并异恶唑环上的生物转化。